A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 1, 2015, Pages 155-165

  Lee, Helen ^a   Zheng, Jinzi ^b   Gaddy, Daniel ^a   Orcutt, Kelly D ^c   Leonard, Shannon ^a   Geretti, Elena ^a   Hesterman, Jacob ^c   Harwell, Catey ^c   Hoppin, Jack ^c   Jaffray, David A ^b   Wickham, Thomas ^a   Hendriks, Bart S ^a   Kirpotin, Dmitri ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c InviCRO LLC   (United States)

Author keywords

64Cu; Drug delivery; Liposome; PET imaging; Tumor deposition

Indexed keywords

CHELATION; DEPOSITION; DRUG DELIVERY; EXPERIMENTS; LIPOSOMES; POSITRONS; TUMORS;

DEPOSITION KINETICS; DETECTION METHODS; DRUG DEPOSITIONS; LIPOSOMAL DOXORUBICIN; LOADING TECHNIQUE; PET IMAGING; POSITRON EMISSION; TREATMENT OUTCOMES;

POSITRON EMISSION TOMOGRAPHY;

CHELATING AGENT; COPPER 64; DIACETYL 4,4' BIS[3 (N,N DIETHYLAMINO)PROPYL]THIOSEMICARBAZONE; DOXORUBICIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; CARBON; COPPER; LIPOSOME; MACROGOL DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; NANOMEDICINE; PROCEDURES; TUMOR CELL LINE;

RODENTIA;

ANIMALS; CARBON ISOTOPES; CELL LINE, TUMOR; CHELATING AGENTS; COPPER; COPPER RADIOISOTOPES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICE; NANOMEDICINE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84919647843     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.08.011     Document Type: Article

References (32)

1. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8(10):2861-2871.
2. Kesner A.L., Hsueh W.-A., Htet N.L., et al. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med 2007, 48(12):2021-2027.
3. Hsueh W.-A., Kesner A.L., Gangloff A., et al. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med 2006, 47(12):1995-1999.
4. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65(1-2):271-284.
5. Dunne M., Zheng J., Rosenblat J., Jaffray D.A., Allen C. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. J Control Release 2011, 154(3):298-305.
6. Kirpotin D.B., Drummond D.C., Shao Y., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66(13):6732-6740.
7. Harrington K.J., Mohammadtaghi S., Uster P.S., et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001, 7(2):243-254.
8. Hendriks B.S., Reynolds J.G., Klinz S.G., et al. Multiscale kinetic modeling of liposomal doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. CPT pharmacometrics Syst Pharmacol 2012, 1(11):e15.
9. Karathanasis E., Suryanarayanan S., Balusu S.R., et al. Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. Radiology 2009, 250(2):398-406.
10. Koukourakis M.I., Koukouraki S., Fezoulidis I., et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000, 83(10):1281-1286.
11. Abou D.S., Thorek D.L.J., Ramos N.N., et al. (89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer. Pharm Res 2013, 30(3):878-888.
12. Petersen A.L., Binderup T., Jølck R.I., et al. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. J Control Release 2012, 160(2):254-263.
13. Petersen A.L., Binderup T., Rasmussen P., et al. 64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials 2011, 32(9):2334-2341.
14. Ting G., Chang C.-H., Wang H.-E., Lee T.-W. Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol 2010, [2010].
15. Li S., Goins B., Zhang L., Bao A. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug Chem 2012, 23(6):1322-1332.
16. Urakami T., Akai S., Katayama Y., Harada N., Tsukada H., Oku N. Novel amphiphilic probes for [18F]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography. J Med Chem 2007, 50(26):6454-6457.
17. Reynolds J.G., Geretti E., Hendriks B.S., et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012, 262(1):1-10.
18. Huang C.Y. Determination of binding stoichiometry by the continuous variation method: the Job plot. Methods Enzymol 1982, 87:509-525.
19. Baranyai Z., Pálinkás Z., Uggeri F., Brücher E. Equilibrium studies on the Gd3+, Cu2+ and Zn2+ complexes of BOPTA, DTPA and DTPA-BMA ligands: kinetics of metal-exchange reactions of [Gd(BOPTA)]2-. Eur J Inorg Chem 2010, 2010(13):1948-1956.
20. Nellis D.F., Ekstrom D.L., Kirpotin D.B., et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 2005, 21(1):205-220.
21. Park J.W., Kirpotin D.B., Hong K., et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001, 74(1-3):95-113.
22. Hoechst F. Bis-Thiosemicarbazones. U.S. Patent 3,520,924. 1970.
23. Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160(2):117-134.
24. Drummond, Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51(4):691-743.
25. Gabizon A., Goren D., Horowitz A.T., Tzemach D., Lossos A., Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997, 24(2-3):337-344.
26. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993, 1151(2):201-215.
27. Jensen G.M., Bunch T.H. Conventional liposome performance and evaluation: lessons from the development of Vescan. J Liposome Res 2007, 17(3-4):121-137.
28. Seo J.W., Mahakian L.M., Kheirolomoom A., et al. Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects. Bioconjug Chem 2010, 21(7):1206-1215.
29. Bao A., Goins B., Klipper R., Negrete G., Phillips W.T. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 2004, 308(2):419-425.
30. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003, 42(5):419-436.
31. Zheng J., Jaffray D., Allen C. Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. Mol Pharm 2009, 6(2):571-580.
32. U.S.National Institute of Health Safety and pharmacokinetic study of MM-302 in patients with advanced breast cancer 2014.